Dammis Vroegindeweij
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dammis Vroegindeweij has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Edwin H. G. Oei
Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
4 shared publications - Jos Runhaar
Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands
4 shared publications - Sita M. A. Bierma-Zeinstra
Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications - Marieke L. A. Landsmeer
Department of General Practice, Erasmus MC, University Medical Center Rotterdam, the Netherlands
3 shared publications - Marienke van Middelkoop
Department of General Practice, Erasmus MC Medical University Center Rotterdam, Rotterdam, the Netherlands
3 shared publications - P. van der Plas
Department of Radiology, Spijkenisse Medical Center, Spijkenisse, the Netherlands
3 shared publications
Latest Publications
- 1 December 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26 (12) , 1666-1674
Effect of weight change on progression of knee OA structural features assessed by MRI in overweight and obese women
- 1 December 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26 (12) , 1666-1674
Effect of weight change on progression of knee OA structural features assessed by MRI in overweight and obese women
- 1 August 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25 (8) , 1299-1303
Baseline meniscal extrusion associated with incident knee osteoarthritis after 30 months in overweight and obese women
- 1 August 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25 (8) , 1299-1303
Baseline meniscal extrusion associated with incident knee osteoarthritis after 30 months in overweight and obese women
- 1 June 2016
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 24 (6) , 982-990
Reducing progression of knee OA features assessed by MRI in overweight and obese women: secondary outcomes of a preventive RCT
- 1 June 2016
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 24 (6) , 982-990
Reducing progression of knee OA features assessed by MRI in overweight and obese women: secondary outcomes of a preventive RCT
- 1 August 2015
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 23 (8) , 1398-1404
Association of urinary biomarker COLL2-1NO2 with incident clinical and radiographic knee OA in overweight and obese women
- 1 August 2015
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 23 (8) , 1398-1404
Association of urinary biomarker COLL2-1NO2 with incident clinical and radiographic knee OA in overweight and obese women
- Open Access
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 87
Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial
Restenosis after percutaneous transluminal angioplasty (PTA) of the superficial femoral artery (SFA) may occur in 45% of patients at 2 years follow-up. Paclitaxel-coated balloons have been found to reduce neointimal hyperplasia, and thus reduce restenosis. Recently, the Legflow® paclitaxel-coated balloon (Cardionovum Sp.z.o.o., Warsaw, Poland) (LPEB) has been introduced. This balloon is covered with shellac, a Food and Drug Administration (FDA) approved natural resin, to obtain an equally distributed tissue concentration of paclitaxel. The RAPID trial is designed to assess restenosis after PTA using the Legflow balloon combined with nitinol stenting versus uncoated balloons with nitinol stenting in SFA lesions >5 cm.
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 87
Open AccessRandomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial
Restenosis after percutaneous transluminal angioplasty (PTA) of the superficial femoral artery (SFA) may occur in 45% of patients at 2 years follow-up. Paclitaxel-coated balloons have been found to reduce neointimal hyperplasia, and thus reduce restenosis. Recently, the Legflow® paclitaxel-coated balloon (Cardionovum Sp.z.o.o., Warsaw, Poland) (LPEB) has been introduced. This balloon is covered with shellac, a Food and Drug Administration (FDA) approved natural resin, to obtain an equally distributed tissue concentration of paclitaxel. The RAPID trial is designed to assess restenosis after PTA using the Legflow balloon combined with nitinol stenting versus uncoated balloons with nitinol stenting in SFA lesions >5 cm.
- Open Access
- 23 January 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 20
Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale
Background: The use of thrombolytic therapy in the treatment of thrombosed infrainguinal native arteries and bypass grafts has increased over the years. Main limitation of this treatment modality, however, is the occurrence of bleeding complications. Low intensity ultrasound (US) has been shown to accelerate enzymatic thrombolysis, thereby reducing therapy time. So far, no randomized trials have investigated the application of US-accelerated thrombolysis in the treatment of thrombosed infra-inguinal native arteries or bypass grafts. The DUET study (Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thrombo-embolic infrainguinal disease) is designed to assess whether US-accelerated thrombolysis will reduce therapy time significantly compared with standard catheter-directed thrombolysis. Methods/design: Sixty adult patients with recently (between 1 and 7 weeks) thrombosed infrainguinal native arteries or bypass grafts with acute limb ischemia class I or IIa, according to the Rutherford classification for acute ischemia, will be randomly allocated to either standard thrombolysis (group A) or US-accelerated thrombolysis (group B). Patients will be recruited from 5 teaching hospitals in the Netherlands during a 2-year period. The primary endpoint is the duration of catheter-directed thrombolysis needed for uninterrupted flow in the thrombosed infrainguinal native artery or bypass graft, with outflow through at least 1 crural artery. Discussion: The DUET study is a randomized controlled trial that will provide evidence of whether US-accelerated thrombolysis will significantly reduce therapy time in patients with recently thrombosed infrainguinal native arteries or bypass grafts, without an increase in complications. Trial registration: Current Controlled Trials ISRCTN72676102
- 23 January 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 20
Open AccessDutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale
Background: The use of thrombolytic therapy in the treatment of thrombosed infrainguinal native arteries and bypass grafts has increased over the years. Main limitation of this treatment modality, however, is the occurrence of bleeding complications. Low intensity ultrasound (US) has been shown to accelerate enzymatic thrombolysis, thereby reducing therapy time. So far, no randomized trials have investigated the application of US-accelerated thrombolysis in the treatment of thrombosed infra-inguinal native arteries or bypass grafts. The DUET study (Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thrombo-embolic infrainguinal disease) is designed to assess whether US-accelerated thrombolysis will reduce therapy time significantly compared with standard catheter-directed thrombolysis. Methods/design: Sixty adult patients with recently (between 1 and 7 weeks) thrombosed infrainguinal native arteries or bypass grafts with acute limb ischemia class I or IIa, according to the Rutherford classification for acute ischemia, will be randomly allocated to either standard thrombolysis (group A) or US-accelerated thrombolysis (group B). Patients will be recruited from 5 teaching hospitals in the Netherlands during a 2-year period. The primary endpoint is the duration of catheter-directed thrombolysis needed for uninterrupted flow in the thrombosed infrainguinal native artery or bypass graft, with outflow through at least 1 crural artery. Discussion: The DUET study is a randomized controlled trial that will provide evidence of whether US-accelerated thrombolysis will significantly reduce therapy time in patients with recently thrombosed infrainguinal native arteries or bypass grafts, without an increase in complications. Trial registration: Current Controlled Trials ISRCTN72676102
- 1 November 1997
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 20 (6) , 413-419
Evaluation of Directional Atherectomy Studied by Intravascular Ultrasound in Femoropopliteal Artery Stenosis
Purpose: To evaluate the role of intravascular ultrasound (IVUS) before and after directional atherectomy (DA) in the treatment of femoropopliteal artery stenosis. Methods: In 12 patients with 16 stenoses IVUS was performed before and immediately after an angiographically successful DA. This was defined as a diameter reduction (DR) ≤ 50%, which was calculated using the minimal lumen diameter compared with the diameter of a nearby ``normal'' segment. In the presence of residual plaque on IVUS an additional DA was performed. Endpoints studied were DR ≤ 30% on IVUS compared with the IVUS findings of the angiographically normal reference segment, or when no additional atherosclerotic material could be removed by further DA passages. Results: Additional DA (mean 1.6 per lesion) had to be performed in all patients. Initial DA increased the cross-sectional free lumen area (FLA) from 3.8 ± 2.0 mm2 to 8.1 ± 2.7 mm2 (p= 0.0004). Additional DA increased FLA to 9.3 ± 2.3 mm2 (p= 0.002) after the second passage and to 9.8 ± 2.4 mm2 (p= 0.09) after the final DA run. The plaque area (PLA) before DA decreased from 18.1 ± 4.2 mm2 to 15.4 ± 4.8 mm2 (p= 0.002) after the first passage, and to 13.5 ± 5.0 mm2 (p= 0.004) and 12.8 ± 4.4 mm2 (p= 0.07) after the second and final DA runs, respectively. PLA of the reference segment (9.5 ± 5.7 mm2) was significantly smaller (p= 0.006) than the final PLA of the treated lesion, indicating a large amount of retained plaque. As a result of DA there was an increase in the area bordered by the medial layer, i.e., the total vessel area (from 21.9 ± 4.7 mm2 to 23.0 ± 4.7 mm2), significantly in eccentric and soft lesions. On IVUS, dissection and plaque rupture after the final passage was seen in 12 of 16 stenoses; two dissections were seen on the completion angiogram. After the final passage in all stenoses except three, the DR with IVUS was ≤ 30%. Conclusion: Lumen enlargement following DA is predominantly due to plaque excision. Vessel expansion combined with plaque excision varies in different stenoses and is an important factor in eccentric and soft lesions. Despite additional DA considerable plaque remains.
- 1 November 1997
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 20 (6) , 413-419
Evaluation of Directional Atherectomy Studied by Intravascular Ultrasound in Femoropopliteal Artery Stenosis
Purpose: To evaluate the role of intravascular ultrasound (IVUS) before and after directional atherectomy (DA) in the treatment of femoropopliteal artery stenosis. Methods: In 12 patients with 16 stenoses IVUS was performed before and immediately after an angiographically successful DA. This was defined as a diameter reduction (DR) ≤ 50%, which was calculated using the minimal lumen diameter compared with the diameter of a nearby ``normal'' segment. In the presence of residual plaque on IVUS an additional DA was performed. Endpoints studied were DR ≤ 30% on IVUS compared with the IVUS findings of the angiographically normal reference segment, or when no additional atherosclerotic material could be removed by further DA passages. Results: Additional DA (mean 1.6 per lesion) had to be performed in all patients. Initial DA increased the cross-sectional free lumen area (FLA) from 3.8 ± 2.0 mm2 to 8.1 ± 2.7 mm2 (p= 0.0004). Additional DA increased FLA to 9.3 ± 2.3 mm2 (p= 0.002) after the second passage and to 9.8 ± 2.4 mm2 (p= 0.09) after the final DA run. The plaque area (PLA) before DA decreased from 18.1 ± 4.2 mm2 to 15.4 ± 4.8 mm2 (p= 0.002) after the first passage, and to 13.5 ± 5.0 mm2 (p= 0.004) and 12.8 ± 4.4 mm2 (p= 0.07) after the second and final DA runs, respectively. PLA of the reference segment (9.5 ± 5.7 mm2) was significantly smaller (p= 0.006) than the final PLA of the treated lesion, indicating a large amount of retained plaque. As a result of DA there was an increase in the area bordered by the medial layer, i.e., the total vessel area (from 21.9 ± 4.7 mm2 to 23.0 ± 4.7 mm2), significantly in eccentric and soft lesions. On IVUS, dissection and plaque rupture after the final passage was seen in 12 of 16 stenoses; two dissections were seen on the completion angiogram. After the final passage in all stenoses except three, the DR with IVUS was ≤ 30%. Conclusion: Lumen enlargement following DA is predominantly due to plaque excision. Vessel expansion combined with plaque excision varies in different stenoses and is an important factor in eccentric and soft lesions. Despite additional DA considerable plaque remains.